Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.06 BRL | +11.54% | -2.17% | -8.76% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- The company's profit outlook over the next few years is a strong asset.
- The company appears to be poorly valued given its net asset value.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 81.92 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Managed Healthcare
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-8.76% | 5.83B | C | ||
-0.52% | 1.2B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HAPV3 Stock
- Ratings Hapvida Participações e Investimentos S.A.